Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024

Nach wie vor hat das Pankreaskarzinom eine ungünstige Prognose. Präventionsmöglichkeiten und Frühsymptome fehlen, sodass die Erkrankung in der Regel erst in einem fortgeschrittenen Stadium diagnostiziert wird. In dieser Situation ist zumeist eine Systemtherapie indiziert, deren Auswahl durch Zulassung neuer Medikamente und Medikamentenkombinationen in den letzten Jahren zunehmend erweitert werden konnte. Der Beitrag erläutert das aktuelle diagnostische und therapeutische Vorgehen.

Schlüsselwörter

Pankreaskarzinom - Tumorausdehnung - Therapiestrategie - Tumormarker - Bauchspeicheldrüse - duktales Adenokarzinom

• Literatur

• 1 Robert Koch-Institut. Krebs in Deutschland für 2019/2020. Zentrum für Krebsregisterdaten, 2019/2020; 14: 52–55. 2023 Accessed August 03, 2024 at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2023.pdf?__blob=publicationFile
• 2 Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: A change is coming. World J Gastroenterol 2021; 27: 1943-1958
• 3 Harder J, Ihorst G, Heinemann V. et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012; 106: 1033-1038
• 4 Humphris JL, Patch A-M, Nones K. et al. Hypermutation In Pancreatic Cancer. Gastroenterology 2017; 152: 68-74e2
• 5 Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2017; 32: 185-203
• 6 Philip PA, Azar I, Xiu J. et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res 2022; 28: 2704-2714
• 7 Seufferlein T, Mayerle J, Böck S. et al. S3-Leitlinie zum exokrinen Pankreaskarzinom. Z Gastroenterol 2022; 60: e812-e909
• 8 Duffy MJ, Sturgeon C, Lamerz R. et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010; 21: 441-447
• 9 Persigehl T, Baumhauer M, Baessler B. et al. Structured Reporting of Solid Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG). Rofo 2020; 192: 641-656
• 10 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18: 2-11
• 11 Tempero MA, Malafa MP, Al-Hawary M. et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19: 439-457
• 12 van der Gaag NA, Rauws EA, Casper HJ. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137
• 13 Hackert T. Surgery for pancreatic cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2018; 2: 413-418
• 14 Koerkamp BG, Janssen QP, van Dam JL. et al. LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial. Ann Oncol 2023; 34 (Suppl. 2) S1254-S1335
• 15 Oettle H, Post S, Neuhaus P. et al. Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277
• 16 Neoptolemos JP, Dunn JA, Stocken DD. et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a radomised controlled trial. Lancet 2001; 358: 1576-1585
• 17 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial. Lancet 2017; 389: 1011-1024
• 18 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406
• 19 Valle JW, Palmer D, Jackson R. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014; 32: 504-512
• 20 Hammel P, Huguet F, van Laethem JL. et al. Effect of Chemoradiotherapy versus Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315: 1844-1853
• 21 Fietkau R, Grützmann R, Wittel UA. et al. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007+-trial. Strahlenther Onkol 2021; 197: 8-18
• 22 Kunzmann V, Siveke JT, Algül H. et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 128-138
• 23 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825
• 24 Goldstein D, El-Maraghi RH, Hammel P. et al. nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015; 107: dju413
• 25 von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703
• 26 Macarulla T, Pazo-Cid R, Guillén-Ponce C. et al. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol 2019; 37: 230-238
• 27 Tong H, Fan Z, Lui B. et al. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep 2018; 8: 8666
• 28 Wainberg Z, Melisi D, Macarulla T. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023; 402: 1272-1281
• 29 Golan T, Hammel P, Reni M. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 2019; 381: 317-327
• 30 Terazawa T, Goto M, Takahiro M. et al. The efficacy of prophylactic GCSF for FOLFIRINOX. J Clin Oncol 2015; 33 (Suppl. 03) 274
• 31 Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178-1179
• 32 Oettle H, Riess H, Stieler JM. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-2429
• 33 Gill S, Ko YJ, Cripps C. et al. PANCREOX: A randomized phase III study of fluorouracil/leukovorin with or without oxaliplatin for second-line advanced pancratic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016; 34: 3914-3920
• 34 Wang-Gillam A, Li CP, Bodoky G. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label, phase 3 trial. Lancet 2016; 387: 545-557
• 35 Portal A, Pernot S, Tougeron D. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicenter cohort. Br J Cancer 2015; 113: 989-995
• 36 De La Fouchardière C, Walka D, Cropet C. et al. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study. J Clin Oncol 2024; 42: 1055-1066
• 37 Taieb J, Sayah L, Heinrich K. et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur J Cancer 2023; 188: 90-97
• 38 Bekaii-Saab T, Yaeger R, Spira A. et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation. J Clin Oncol 2023; 41: 4097-4106
• 39 Strickler J, Satake H, George T. et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 2023; 388: 33-43
• 40 Sacher A, LoRusso P, Patel MR. et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389: 710-721
• 41 Kim D, Herdeis L, Rudolph D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 2023; 619: 160-166